<DOC>
	<DOCNO>NCT00257881</DOCNO>
	<brief_summary>The primary purpose study evaluate safety , tolerability , maximum tolerate dose ( MTD ) CMD-193 administer intravenously ( IV ) subject advanced malignant tumor . The secondary purpose obtain preliminary information pharmacokinetics antitumor activity IV CMD-193 .</brief_summary>
	<brief_title>Study Evaluating Intravenous CMD-193 Subjects With Advanced Malignant Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Malignant solid tumor progress , standard treatment available Tumor expression Lewis Y antigen Cancer therapy within 28 day enrollment Pregnant breastfeed woman Unstable serious concurrent medical condition</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Tumor</keyword>
</DOC>